No. 25A304
Jazz Pharmaceuticals, Inc. v. Robert F. Kennedy, Secretary of Health and Human Services, et al.
Tags: administrative-law chevron-deference fda-regulation market-exclusivity orphan-drug-act statutory-interpretation
Latest Conference:
N/A
Question Presented (from Petition)
Question not identified.
Question Presented (AI Summary)
Whether Congress implicitly ratified an FDA regulatory interpretation of the Orphan Drug Act's market exclusivity provision when it amended the statutory language without explicitly addressing the agency's longstanding regulatory construction
Docket Entries
2025-09-16
Application (25A304) granted by The Chief Justice extending the time to file until November 10, 2025.
2025-09-12
Application (25A304) to extend the time to file a petition for a writ of certiorari from September 25, 2025 to November 10, 2025, submitted to The Chief Justice.
Attorneys
Food & Drug Administration, et al.
D. John Sauer — Solicitor General, Respondent
Jazz Pharmaceuticals, Inc.
Carter G. Phillips — Sidley Austin LLP, Petitioner